De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Oryzon Genomics Beheer

Beheer criteriumcontroles 2/4

De CEO Oryzon Genomics' is Carlos Manuel Arjol, benoemd in Jan2000, heeft een ambtstermijn van 24.75 jaar. bezit rechtstreeks 4.61% van de aandelen van het bedrijf, ter waarde € 5.26M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.7 jaar en 8.9 jaar.

Belangrijke informatie

Carlos Manuel Arjol

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	24.8yrs
Eigendom CEO	4.6%
Management gemiddelde ambtstermijn	5.7yrs
Gemiddelde ambtstermijn bestuur	8.9yrs

Recente managementupdates

Recent updates

Growth Investors: Industry Analysts Just Upgraded Their Oryzon Genomics S.A. (BME:ORY) Revenue Forecasts By 54%

Oct 03

Oryzon Genomics S.A. (BME:ORY) Screens Well But There Might Be A Catch

Jun 09

Is Oryzon Genomics (BME:ORY) Using Too Much Debt?

Apr 04

Industry Analysts Just Made A Dazzling Upgrade To Their Oryzon Genomics S.A. (BME:ORY) Revenue Forecasts

Jul 24

Is Oryzon Genomics (BME:ORY) Weighed On By Its Debt Load?

May 01

Oryzon Genomics (BME:ORY) Has Debt But No Earnings; Should You Worry?

Feb 26

If You Had Bought Oryzon Genomics (BME:ORY) Shares A Year Ago You'd Have Earned 18% Returns

Jan 04

CEO

Carlos Manuel Arjol

24.8yrs

Tenure

€58,000

Compensatie

Dr. Carlos Manuel Buesa Arjol Co-Founded Oryzon Genomics S.A. in 2000 and has been its Chairman and Chief Executive Officer since 2001 and serves as its President and served as its Member of Financial Advi...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Carlos Manuel Arjol	Co-Founder	24.8yrs	€58.00k	4.61% € 5.3m
Enric Condomines	Director of Operations	4.3yrs	geen gegevens	geen gegevens
Jordi Pey	Chief Scientific Officer	3.8yrs	geen gegevens	geen gegevens
Xavier Ribera	Head of Internal Audit & Compliance	no data	geen gegevens	geen gegevens
Emili Cortada	Chief Business Development Officer	no data	geen gegevens	geen gegevens
Neus Bernado	Chief Intellectual Property Officer	13.1yrs	geen gegevens	geen gegevens
Michael Ropacki	Chief Medical Officer of CNS	3.8yrs	geen gegevens	geen gegevens
Sonia Paloma Bezon	Chief of Clinical Operations	7yrs	geen gegevens	geen gegevens
Augusto Rubio	Secretary	no data	geen gegevens	geen gegevens

5.7yrs

Gemiddelde duur

Ervaren management: Het managementteam van ORY is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Carlos Manuel Arjol	Co-Founder	23.8yrs	€58.00k	4.61% € 5.3m
Howard Fillit	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Isabel Aguilera Navarro	Independent Director	8.9yrs	€7.00k	geen gegevens
Lori Kunkel	Member of Scientific Advisory Board	6.7yrs	geen gegevens	geen gegevens
Manuel López-Figueroa	Lead Independent Director	4.4yrs	geen gegevens	geen gegevens
Josep Echarri Torres	Director	22.7yrs	€6.00k	1.98% € 2.3m
Tamara Maes	VP of the Board & President of Scientific Advisory Board	24.8yrs	€58.00k	3.96% € 4.5m
Ramon Ramon	Independent Director	8.9yrs	€7.00k	0.029% € 33.4k
Leon Hooftman	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Antonio Melero	Independent Director	8.9yrs	€7.00k	geen gegevens
Felipe Cardoso	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jose Molinuevo	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

8.9yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ORY wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.9 jaar).

Oryzon Genomics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

Oryzon Genomics S.A. Announces Appointment of Douglas V. Faller as Global Chief Medical Officer

Oryzon Genomics S.A. Announces Executive Changes

Recent updates

Growth Investors: Industry Analysts Just Upgraded Their Oryzon Genomics S.A. (BME:ORY) Revenue Forecasts By 54%

Consensus revenue estimates increase by 54%

No longer forecast to breakeven

Forecast to breakeven in 2025

New minor risk - Shareholder dilution

No longer forecast to breakeven

Oryzon Genomics, S.A. Announces Presentation of Final Data from Portico, Vafidemstat's Global Phase IIb Trial in Borderline Personal Disorder, at the 37th ECNP Annual Conference

Oryzon Genomics S.A. Presents Preliminary Data from Ongoing Phase Ib Frida Trial with Iadademstat Plus Gilteritinib in Relapsed/Refractory Flt3-Mut Aml Patients At Eha-2024

Forecast breakeven date moved forward to 2025

Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat

Forecast breakeven date pushed back to 2026

ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer

New major risk - Share price stability

New major risk - Revenue and earnings growth

New minor risk - Profitability

Forecast breakeven date pushed back to 2026

Oryzon Genomics, S.A. Announces Topline Results from Phase IIb Portico Study of Vafidemstat in Borderline Personality Disorder

Oryzon Genomics S.A. announced that it expects to receive €45 million in funding from Nice & Green SA

Oryzon Genomics S.A. announced that it expects to receive €45 million in funding from Nice & Green SA

Oryzon Genomics, S.A. Announces Last Patient Last Visit in Its Phase IIb Portico Study for Borderline Personality Disorder

Oryzon Genomics, S.A. Presents Blinded Aggregated Safety Data from Vafidemstat's Ongoing Phase IIB Portico Trial in Borderline Personal Disorder

Forecast to breakeven in 2025

New major risk - Financial position

Forecast to breakeven in 2025

Oryzon Genomics, S.A. Reports New Preliminary Blinded Aggregate Safety Data from Its Ongoing Phase IIb Portico Trial

Oryzon Genomics, S.A. Presents Positive Preclinical Data of Ory-4001 for the Treatment of Charcot-Marie-Tooth Disease Presented At the 2023 Peripheral Nerve Society Annual Meeting

New minor risk - Share price stability

Oryzon Genomics S.A. (BME:ORY) Screens Well But There Might Be A Catch

Insufficient new directors

Oryzon Genomics, S.A. to Present Positive Preclinical Efficacy Data of ORY-4001 in Charcot-Marie-Tooth (CMT) Disease At the 2023 Peripheral Nerve Society Annual Meeting

Forecast to breakeven in 2025

Is Oryzon Genomics (BME:ORY) Using Too Much Debt?

Oryzon Genomics S.A. announced that it has received €1.800407 million in funding

Price target decreased to €8.83

ORYZON Announces FDA Clearance of IND to Initiate a Collaborative Phase II Basket Study with Iadademstat in R/R Patients with Neuroendocrine Carcinomas (NECs)

Consensus forecasts updated

Consensus forecasts updated

Industry Analysts Just Made A Dazzling Upgrade To Their Oryzon Genomics S.A. (BME:ORY) Revenue Forecasts

Oryzon Genomics S.A. announced that it expects to receive €20 million in funding from Nice & Green SA

Oryzon Genomics S.A. At Eha-2022: Iadademstat 42-Month Alice Data Demonstrate Robust Efficacy in Combination with Azacitidine in AML

Oryzon Starts Preclinical Collaboration on Kabuki Syndrome with Kennedy Krieger Institute and Johns Hopkins University

Is Oryzon Genomics (BME:ORY) Weighed On By Its Debt Load?

Price target decreased to €9.00

Oryzon Genomics S.A. Announces Appointment of Douglas V. Faller as Global Chief Medical Officer

Price target increased to €12.00

Full year 2021 earnings: EPS misses analyst expectations

ORYZON Announces Approval for Serbian Arm of PORTICO, Vafidemstat’s Phase IIb Trial in Borderline Personality Disorder

Oryzon Genomics S.A. Presents Iadademstat 36-Month Alice Data Demonstrate Robust Efficacy in Combination with Azacitidine in AML

Oryzon Announces $1 Million Grant from Kabuki Syndrome Philanthropists to Support A Precision Medicine Phase I/Ii Trial with Vafidemstat

First half 2021 earnings released: €0.019 loss per share (vs €0.026 loss in 1H 2020)

Oryzon Genomics S.A. Receives Approval to Start EVOLUTION Phase IIb trial with vafidemstat in schizophrenia

Oryzon Genomics, S.A. Announces FDA Approval of IND for Portico, Phase IIb Trial with Vafidemstat in Borderline Personality Disorder

ORYZON Presents Iadademstat ALICE 30-Month Data at EHA-2021, Confirming Positive and Robust Efficacy in Combination with Azacitidine in AML

ORYZON to Present New Clinical Data

Oryzon Genomics, S.A. Announces Successful pre-IND Meeting with FDA for the Clinical Development of vafidemstatin Borderline Personality Disorder

Oryzon Genomics S.A. Presents Vafidemstat 12-Month Clinical Data from Its Phase IIa Clinical Trials

Oryzon Genomics (BME:ORY) Has Debt But No Earnings; Should You Worry?

Earnings miss expectations

Full year 2020 earnings released

New 90-day high: €3.72

If You Had Bought Oryzon Genomics (BME:ORY) Shares A Year Ago You'd Have Earned 18% Returns

Oryzon Genomics S.A. Launches Pioneering Schizophrenia Precision Medicine Study in Collaboration with Columbia Psychiatry

New 90-day high: €3.21

New 90-day low: €2.70

Oryzon Genomics S.A. to Present Further Positive Efficacy Data From Iadademstat ALICE Phase IIa Trial at the 62nd Congress of the American Society of Hematology

Oryzon Genomics, S.A. Receives Approval to Start PORTICO Phase IIb Trial with Vafidemstat in Borderline Personality Disorder

Oryzon Genomics S.A. Announces Executive Changes

Third quarter earnings released

New 90-day low: €2.70

Oryzon Genomics S.A. has completed a Follow-on Equity Offering in the amount of €20.00075 million.

CEO

Tenure